Author

G. Hussack

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1 Assay:protein structure· 1 Assay:proteomics· 1

Frequent Co-Authors

H. Van Faassen· 2 shared J. Tanha· 2 shared A. Tran· 1 shared C. Gervais· 1 shared D. Chouljenko· 1 shared D. Duque· 1 shared G. Dayer· 1 shared G. Laroche· 1 shared

Activity by Year

2018-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

H. Van Faassen

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

HSV-1 Oncolytic Virus Targeting CEACAM6-Expressing Tumors Using a Bispecific T-Cell Engager

Y. M. Murad, I.-F. Lee, X. Liu, Z. Delwar, J. Ding, G. Liu, O. Tatsiy, D. Chouljenko, G. Hussack, H. Van Faassen, W. W.-G. Jia

This paper describes a novel oncolytic virus encoding a bispecific T-cell engager targeting CEACAM6-expressing tumors, showing enhanced anti-tumor efficacy and safety in vitro and in vivo.

bioRxiv · Jan 2, 2023 · PreprintCancer Biology

Arsenal of Nanobodies for Broad-Spectrum Countermeasures against Current and Future SARS-CoV-2 Variants of Concerns

M. A. Rossotti, H. van Faassen, A. Tran, J. Sheff, J. A. Sandhu, D. Duque, M. Hewitt, S. Wen, R. Bavananthasivam, S. Beitari, K. Matte, G. Laroche, P. M. Giguere, C. Gervais, M. Stuible, , J. Tanha

This paper presents a diverse set of nanobodies targeting SARS-CoV-2 spike glycoprotein with broad neutralization activity against multiple variants and high in vivo efficacy.

bioRxiv · Dec 20, 2021 · PreprintBioengineering

Single-domain antibodies represent novel alternatives to monoclonal antibodies as targeting agents against the human papillomavirus 16 E6 protein

M. Togtema, G. Hussack, G. Dayer, M. Teghtmeyer, S. Raphael, J. Tanha, I. Zehbe

This study identifies VHHs that bind HPV16 E6 protein with nanomolar affinity, offering potential as novel targeting agents for HPV16-related cancers.

bioRxiv · Aug 9, 2018Cancer Biology